Our researchers have made a discovery that could change how patients with head and neck cancers are treated. The study’s results mean that there may be therapeutic value in testing tumors for two genetic identifiers, TP53 mutation (short for tumor protein 53) and a 3p deletion (short for deletions of genetic information on the short arm “p” of the third chromosome). The study’s findings suggest that if both markers are present, treatment should be intensified. If only one mutation is present, treatment might be de-intensified because the TP53 mutation alone is less deadly than previously thought. The latter would have immediate benefits in reducing deaths caused by complications related to medical care.
Posted on: Mon, 04 Aug 2014 17:33:52 +0000
Trending Topics
Recently Viewed Topics
© 2015